Start strong or switch? Adjuvant endocrine strategies for postmenopausal women with hormone-sensitive breast cancer

Biomedicine and Pharmacotherapy

Volumn 63, Issue 1, 2009, Pages 1-10

  Tusquets Trías de Bes, Ignasi ^a   Servitja Tormo, Sònia ^a   Albanell Mestres, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Exemestane; Letrozole

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ANGINA PECTORIS; ARTHRALGIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; CANCER RELAPSE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FEMALE; FRACTURE; HEART FAILURE; HIGH RISK POPULATION; HORMONAL THERAPY; HOSPITALIZATION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; LYMPH NODE METASTASIS; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NIGHT SWEAT; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RISK REDUCTION; SHORT SURVEY; SURVIVAL; VAGINA BLEEDING; VAGINA DISCHARGE; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; POSTMENOPAUSE;

EID: 58149154967     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.04.005     Document Type: Short Survey

References (49)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Saphner T., Tormey D.C., and Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14 (1996) 2738-2746
3. Doughty J.C., Wilson C.R., Monypenny I.J., Skene A.I., Abram P., Gattuso J., et al. Distant metastasis: the most common type of early recurrence with adjuvant tamoxifen therapy. Breast Cancer Res Treat 106 Suppl. 1 (2007) S145 [Abstract 3057]
4. Lamerato L., Havstad S., Gandhi S., Jones D., and Chlebowski R. Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 23 16 Suppl. (2005) 62s [Abstract 738]
5. Carreno G., Del Casar J.M., Corte M.D., Gonzalez L.O., Bongera M., Merino A.M., et al. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics. Breast Cancer Res Treat 102 (2006) 61-73
6. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
7. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al., ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
8. Thürlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
9. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
10. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
11. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. Intergroup exemestane study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
12. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
13. Houghton J., and on behalf of the ATAC Trialists' Group. Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events: updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial. J Clin Oncol 23 Suppl. 16 (2005) 24S [Abstract 582]
14. Lawrence G., Pritchard M.G., Kearins O., and Casey M. An analysis of breast cancer recurrences for screen detected and symptomatic breast cancers diagnosed in the West Midlands in 1996 and 1997. Breast Cancer Res Treat 94 Suppl. 1 (2005) S211 [Abstract 5019]
15. Thames H.D., Bucholz T.A., and Smith C.D. Frequency of first metastatic events in breast cancer: implications for sequencing of systemic and local-regional treatment. J Clin Oncol 17 (1999) 2649-2658
16. Kryj M., Maciejewski B., Withers H.R., and Taylor J.M. Incidence and kinetics of distant metastases in patients with operable breast cancer. Neoplasma 44 (1997) 3-11
17. Rugo H.S. Adjuvant therapies: distant disease-free survival as a predictor of overall survival. Breast 16 Suppl. 1 (2007) [Abstract 120]
18. Winer E.P., Hudis C., Burstein H.J., Wolff A.C., Pritchard K.I., Ingle J.N., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 (2005) 619-629
19. NCCN clinical practice guidelines in oncology™: Breast Cancer. V. 2.2007. Available from:.
20. Secretariat E.B.C.T.C.G. Highlights from the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) worldwide overview. on behalf of EBCTCG. Breast Cancer Res Treat 100 Suppl. 1 (2006) [Abstract 40]
21. McArthur H.L., Olivotto I., Gelmon K.A., Speers C.H., Chia S., Ellard S., et al. Risk of early relapse in post-menopausal women with early stage, estrogen receptor positive (ER+) breast cancer on tamoxifen. Breast Cancer Res Treat 94 Suppl. 1 (2005) [Abstract 3001]
22. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
23. McDonald C.C., Alexander F.E., Whyte B.W., Forrest A.P., Stewart H.J., and The Scottish Cancer Trials Breast Group. Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. Br Med J 311 (1995) 977-980
24. Braithwaite R.S., Chlebowski R.T., Lau J., George S., Hess R., and Col N.F. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 (2003) 937-947
25. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Panel members Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
26. Baum M., Buzdar A.V., Cuzick J., Forbes J., Houghton J.H., Klijn J.C., et al., ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
27. Houghton J. Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T) - data reported on behalf of the ATAC ('Arimidex', tamoxifen, alone or in Combination) Trialists' group. Ann Oncol 17 Suppl. 9 (2006) ix94 [Abstract 243PD]
28. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
29. Buzdar A., Howell A., Cuzick J., Wale C., Distler W., Hoctin-Boes G., et al., The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
30. Cuzick J., Wale C., and on behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Breast Cancer Res Treat 100 Suppl. 1 (2006) S24 [Abstract 104]
31. Duffy S., and on behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years follow-up. Breast Cancer Res Treat 100 Suppl. 1 (2006) S190 [Abstract 4055]
32. Mauriac L., Keshaviah A., Debled M., Mouridsen H., Forbes J.F., Thürlimann B., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18 (2007) 859-867
33. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., et al. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. J Clin Oncol 24 (2006) 18S [Abstract 547]
34. DeBoer R., Burris H., Monnier A., Mouridsen H., O'Shaughnessy J., McIntyre K., et al. The Head to Head trial: letrozole vs anastrozole as adjuvant treatment of postmenopausal patients with node positive breast cancer. J Clin Oncol 24 18S (2006) 582s [Abstract 10672]
35. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369 (2007) 559-570
36. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
37. Boccardo F., Rubagotti A., Guglielmini P., Fini A., Paladini G., Mesiti M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17 Suppl. 7 (2006) vii10-vii14
38. Boccardo F.M., Rubagotti A., Puntoni M., Guglielmini P., Porpiglia M., Mesiti M., et al., other ITA trialists. Switching to anastrozole (ANA) vs continued TAM (TAM) treatment of early breast cancer (EBC). Updated results of the Italian TAM anastrozole (ITA) trial. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 25 16S (2005) 10s [Abstract 526]
39. Boccardo F., Rubagotti A., Aldrighetti D., Buzzi F., Cruciani G., Farris A., et al. Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. Cancer 109 (2007) 1060-1067
40. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25 (2007) 2664-2670
41. Pritchard K.I. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J Clin Oncol 23 (2005) 4850-4852
42. Jakesz R., Gnant M., Greil R., Tausch C., Samonigg H., Kwasny W., et al. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 94 Suppl. 1 (2005) S10 [Abstract 13]
43. Jonat W., Gnant M., Boccardo F., Kaufmann M., Rubagotti A., Zuna I., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7 (2006) 991-996
44. Jonat W., Gnant M., Boccardo F., Kaufmann M., Rubagotti A., and Jakesz R. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG trial 8, and the ITA trial. Breast Cancer Res Treat 94 Suppl. 1 (2005) S11 [Abstract 18]
45. Azria D., Tubiana-Hulin M., Spielmann M., Coudert B., Monnier A., Serin D., et al. Prognostic factor for early versus late relapse in non metastatic hormonodependent breast cancers (HBC) treated by tamoxifen. Breast Cancer Res Treat 100 Suppl. 1 (2006) [Abstract 6047]
46. Dignam J.J., Dukic V.M., Anderson S.J., Mamounas E.P., Jeong J.H., and Costantino J.P. Time-dependent patterns of recurrence after early stage breast cancer: preliminary observations and methodological issues. J Clin Oncol 25 18S (2007) 11s [Abstract 536]
47. Bria E., Ciccarese M., Giannarelli D., Cuppone F., Nisticó C., Nuzzo C., et al. Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients. Cancer Treat Rev 32 (2006) 325-332
48. Cuzick J., Sasieni P., and Howell A. Optimal use of aromatase inhibitors for adjuvant treatment of hormone-sensitive early breast cancer: up front or sequential after tamoxifen?. J Clin Oncol 25 (2007) 18S [Abstract 541]
49. Punglia R.S., Kuntz K.M., Winer E.P., Weeks J.C., and Burstein H.J. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol 23 (2005) 5178-5187